TDO2 and hepatocellular carcinoma: Since the expression of immune checkpoints has become a biomarker of immunotherapy for HCC patients, we also analyzed the correlation between patient risk score and key immune checkpoints (CTLA4, PDL1, LAG3, TIGIT, IDO1, TDO2).